AstraZeneca: Tagrisso Met Primary Goal In Phase III 2nd-Line Lung Cancer Trial - Nasdaq

Reuters

AstraZeneca: Tagrisso Met Primary Goal In Phase III 2nd-Line Lung Cancer Trial Nasdaq (RTTNews.com) - AstraZeneca PLC (AZN.L, AZN) announced Monday that the Phase III AURA3 trial met its primary endpoint. Lung cancer drug Tagrisso demonstrated superior progression-free survival compared to standard platinum-based chemotherapy, ... AstraZeneca's lung cancer drug meets main goal in late-stage trialDaily Mail all 7 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNHm6SAq2kaN8I8BZsa5u2mAEvUFAw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779161934541&ei=0ImMV6DOGsyK3QHTi4HwCw&url=http://www.nasdaq.com/article/astrazeneca-tagrisso-met-primary-goal-in-phase-iii-2ndline-lung-cancer-trial-20160718-00042
via IFTTT